Efficacy and safety of immune checkpoint inhibitor rechallenge therapy in the treatment of advanced acquired immune-resistant non-small cell lung cancer: a retrospective study
{{output}}
Background: Patients with advanced non-small cell lung cancer who have failed first-line immunotherapy and lack driver gene mutations face limited options for subsequent treatment. A working group recently proposed updated clinic... ...
